CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA

Phase 4

Terminated

Conditions: Asthma

Interventions: Drug: Administration via pressurized metered dose inhaler (pMDI)

First Posted Date: 2021-08-24

Last Posted Date: 2024-11-15

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 320

Registration Number: NCT05018598

Locations: 🇭🇺
Simplex Kft, Nyíregyháza, Hungary

Expanded Access to Velmanase Alfa

Conditions: Alpha-Mannosidosis

First Posted Date: 2021-07-13

Last Posted Date: 2023-09-25

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Registration Number: NCT04959240

Study in Adult Patients With Moderate to Severe Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Behavioral: Exploratory study on patient's perception of Asthma symptoms

First Posted Date: 2021-05-14

Last Posted Date: 2024-02-20

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 78

Registration Number: NCT04886999

Locations: 🇮🇹
Chiesi 38011, Bari, Italy
🇮🇹
Chiesi 38009, Battipaglia, Italy
🇮🇹
Chiesi 38006, Cagliari, Italy

and more 7 locations

Functional Respiratory Imaging Study

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium

First Posted Date: 2021-05-06

Last Posted Date: 2022-01-25

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 25

Registration Number: NCT04876677

Locations: 🇧🇪
AZ Zeno Knokke-Heist, Knokke, Belgium
🇧🇪
AZ Delta, Roeselare, Belgium
🇭🇺
CRU Hungary Ltd, Miskolc, Hungary

and more 5 locations

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
COPD

Interventions: Drug: CHF6001

First Posted Date: 2021-02-16

Last Posted Date: 2024-03-18

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 8

Registration Number: NCT04756960

Locations: 🇬🇧
Covance - Clinical Research Unit, Leeds, United Kingdom

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF6001 DPI
Drug: Itraconazole

First Posted Date: 2021-02-05

Last Posted Date: 2021-05-05

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 24

Registration Number: NCT04739774

Locations: 🇧🇪
SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

Phase 4

Withdrawn

Conditions: COPD

Interventions: Drug: Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg
Drug: Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg

First Posted Date: 2020-12-17

Last Posted Date: 2022-02-03

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Registration Number: NCT04671355

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

Phase 3

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF6001 3200µg
Drug: Placebo
Drug: Roflumilast
Drug: CHF6001 1600µg

First Posted Date: 2020-11-19

Last Posted Date: 2024-04-18

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 3980

Registration Number: NCT04636814

Locations: 🇧🇬
Chiesi Clinical Trial - Site 100527, Lovech, Bulgaria
🇧🇬
Chiesi Clinical Trial - Site 100533, Kozloduy, Bulgaria
🇺🇸
Chiesi Clinical Trial - Site 840724, Muncie, Indiana, United States

and more 438 locations

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

Phase 3

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo

First Posted Date: 2020-11-19

Last Posted Date: 2024-08-01

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 3435

Registration Number: NCT04636801

Locations: 🇺🇸
Chiesi Clinical Trial - Site 840404, Hollywood, Florida, United States
🇺🇸
Chiesi Clinical Trial - Site 840444, Miami, Florida, United States
🇺🇸
Chiesi Clinical Trial - Site 840437, Miami, Florida, United States

and more 428 locations

Study on Patterns of Care in Mild Asthmatic Patients

Completed

Conditions: Asthma

First Posted Date: 2020-10-22

Last Posted Date: 2022-09-27

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 981

Registration Number: NCT04598555

Locations: 🇩🇪
DE-008 Lungenarztpraxis Hellersdorf, Berlin, Germany
🇩🇪
DE-005 Praxis für Pneumologie und Innere Medizin, Fürstenwalde, Germany
🇩🇪
DE-003 Praxis Pneumologie und Allergologie Dr. Ginko, Bonn, Germany

and more 56 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy